Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Top Companies in In Vitro Diagnostics Market
13 views
Skip to first unread message
Nicole Green
Dec 5, 2023, 11:42:50โฏPM12/5/23
to
The in vitro diagnostics market is expected to achieve a value of USD 138.4 billion by 2027, up from USD 117.8 billion in 2022, with a compound annual growth rate (CAGR) of 3.3% throughout the forecast period. The market's expansion is propelled by the gradual transition from centralized testing to point-of-care testing and the increasing awareness of early disease diagnosis in emerging markets.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703&utm_source=Groups&utm_medium=K
This market is characterized by high competition, with several companies holding significant market shares. Key players in the in vitro diagnostic (IVD) market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMรฉrieux SA (France), Agilent Technologies, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).
Companies in the IVD market are employing various strategies, such as partnerships, agreements, acquisitions, product launches, and expansions, to strengthen their presence in the market.
Roche Diagnostics (Switzerland) stands out as a leading player in the in vitro diagnostics market, holding the largest market share in 2021. The company offers a diverse product portfolio, encompassing clinical chemistry, immunochemistry, molecular diagnostics, tissue diagnostic instruments, reagents, and kits. With a substantial geographic presence spanning North America, Europe, the Middle East, Africa, and Asia, Roche is well-positioned to serve customers globally.
Abbott Laboratories (US) is another significant player in the in vitro diagnostics market, with a strong presence in the US. The company aims to further expand its geographical reach by strengthening operations in emerging and high-growth markets. Abbott boasts a robust product portfolio, and its FDA- and CE-approved products have contributed to maintaining and enhancing its presence in the IVD market.
Danaher Corporation (US) operates across Europe, North America, and the Asia Pacific, with 242 manufacturing and distribution facilities worldwide. Through subsidiaries like Beckman Coulter Inc. (US), Leica Biosystems GmbH (Germany), Cepheid (US), HemoCue AB (Sweden), AB SCIEX Pte. Ltd. (US), and Radiometer Medical ApS (Denmark), Danaher strengthens its position in the IVD market by expanding its product and service offerings. For instance, the acquisition of Aldevron (US) in August 2021 broadened Danaher's capabilities in genomic medicine, life-saving therapies, and vaccines.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703&utm_source=Groups&utm_medium=K
This market is characterized by high competition, with several companies holding significant market shares. Key players in the in vitro diagnostic (IVD) market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMรฉrieux SA (France), Agilent Technologies, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).
Companies in the IVD market are employing various strategies, such as partnerships, agreements, acquisitions, product launches, and expansions, to strengthen their presence in the market.
Roche Diagnostics (Switzerland) stands out as a leading player in the in vitro diagnostics market, holding the largest market share in 2021. The company offers a diverse product portfolio, encompassing clinical chemistry, immunochemistry, molecular diagnostics, tissue diagnostic instruments, reagents, and kits. With a substantial geographic presence spanning North America, Europe, the Middle East, Africa, and Asia, Roche is well-positioned to serve customers globally.
Abbott Laboratories (US) is another significant player in the in vitro diagnostics market, with a strong presence in the US. The company aims to further expand its geographical reach by strengthening operations in emerging and high-growth markets. Abbott boasts a robust product portfolio, and its FDA- and CE-approved products have contributed to maintaining and enhancing its presence in the IVD market.
Danaher Corporation (US) operates across Europe, North America, and the Asia Pacific, with 242 manufacturing and distribution facilities worldwide. Through subsidiaries like Beckman Coulter Inc. (US), Leica Biosystems GmbH (Germany), Cepheid (US), HemoCue AB (Sweden), AB SCIEX Pte. Ltd. (US), and Radiometer Medical ApS (Denmark), Danaher strengthens its position in the IVD market by expanding its product and service offerings. For instance, the acquisition of Aldevron (US) in August 2021 broadened Danaher's capabilities in genomic medicine, life-saving therapies, and vaccines.
0 new messages